Literature DB >> 30074458

Endonasal endoscopic resection of olfactory neuroblastoma: an 11-year experience.

Gary L Gallia1,2,3, Anthony O Asemota1, Ari M Blitz4, Andrew P Lane2, Wayne Koch2, Douglas D Reh1,2, Masaru Ishii1,2.   

Abstract

OBJECTIVE: Olfactory neuroblastoma (ONB) is a rare malignant neoplasm of the sinonasal cavity. Surgery has been and remains a mainstay of treatment for patients with this tumor. Open craniofacial resections have been the treatment of choice for many decades. More recently, experience has been growing with endoscopic approaches in the management of patients with ONB. The object of this study is to report the authors' experience over the past 11 years with ONB patients treated with purely endonasal endoscopic techniques.
METHODS: The authors performed a retrospective chart review of 20 consecutive patients with ONB who underwent a completely endonasal endoscopic approach for an oncological tumor resection at their institution between January 2006 and January 2017. Patient demographics, tumor stage, pathological grade, frozen section analysis, permanent margin assessment, perioperative complications, postoperative therapy, length of follow-up, and outcomes at last follow-up were collected and analyzed.
RESULTS: Eighteen patients presented with newly diagnosed disease, with a modified Kadish stage of A in 2 cases, B in 3, C in 11, and D in 2. Two patients presented with recurrent tumors. An average of 25.3 specimens per patient were examined by frozen section analysis. Although analysis of intraoperative frozen section margins was negative in all but 1 case, microscopic foci of tumor were found in 7 cases (35%) on permanent histopathological analysis. Perioperative complications occurred in 7 patients (35%) including 1 patient who developed a cerebrospinal fluid leak; there were no episodes of meningitis. All but 1 patient received postoperative radiotherapy, and 5 patients received postoperative chemotherapy. With a mean follow-up of over 5 years, 19 patients were alive and 1 patient died from an unrelated cause. There were 2 cases of tumor recurrence. The 5-year overall, disease-specific, and recurrence-free survival rates were 92.9%, 100%, and 92.9%, respectively.
CONCLUSIONS: The current results provide additional evidence for the continued use of endoscopic procedures in the management of this malignancy.

Entities:  

Keywords:  CFR = craniofacial resection; DFS = disease-free survival; DSS = disease-specific survival; FDG = 2-deoxy-2-[18F]fluoro-d-glucose; IQR = interquartile range; JHH = Johns Hopkins Hospital; ONB = olfactory neuroblastoma; OS = overall survival; RFS = recurrence-free survival; endoscopic; esthesioneuroblastoma; frozen section analysis; margin; olfactory neuroblastoma; oncology; outcomes; skull base surgery

Year:  2018        PMID: 30074458     DOI: 10.3171/2018.2.JNS171424

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  5 in total

1.  Clinical Outcomes and Multidisciplinary Patterns of Failure for Olfactory Neuroblastoma: The Ohio State Experience.

Authors:  Adam R Wolfe; Dukagjin Blakaj; Nyall London; Adriana Blakaj; Brett Klamer; Jeff Pan; Paul Wakely; Luciano Prevedello; Marcelo Bonomi; Aashish Bhatt; Raju Raval; Joshua Palmer; Daniel Prevedello; Mauricio Gamez; Ricardo Carrau
Journal:  J Neurol Surg B Skull Base       Date:  2019-06-12

2.  Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.

Authors:  Matt Lechner; Yoko Takahashi; Mario Turri-Zanoni; Jacklyn Liu; Nicholas Counsell; Mario Hermsen; Raman Preet Kaur; Tianna Zhao; Murugappan Ramanathan; Volker H Schartinger; Oscar Emanuel; Sam Helman; Jordan Varghese; Jozsef Dudas; Herbert Riechelmann; Susanne Sprung; Johannes Haybaeck; David Howard; Nils Wolfgang Engel; Sarah Stewart; Laura Brooks; Jessica C Pickles; Thomas S Jacques; Tim R Fenton; Luke Williams; Francis M Vaz; Paul O'Flynn; Paul Stimpson; Simon Wang; S Alam Hannan; Samit Unadkat; Jonathan Hughes; Raghav Dwivedi; Cillian T Forde; Premjit Randhawa; Simon Gane; Jonathan Joseph; Peter J Andrews; Gary Royle; Alessandro Franchi; Roberta Maragliano; Simonetta Battocchio; Helen Bewicke-Copley; Christodoulos Pipinikas; Amy Webster; Chrissie Thirlwell; Debbie Ho; Andrew Teschendorff; Tianyu Zhu; Christopher D Steele; Nischalan Pillay; Bart Vanhaesebroeck; Ahmed Mohyeldin; Juan Fernandez-Miranda; Ki Wan Park; Quynh-Thu Le; Robert B West; Rami Saade; R Peter Manes; Sacit Bulent Omay; Eugenia M Vining; Benjamin L Judson; Wendell G Yarbrough; Maddalena Sansovini; Nicolini Silvia; Ilaria Grassi; Alberto Bongiovanni; David Capper; Ulrich Schüller; Selvam Thavaraj; Ann Sandison; Pavol Surda; Claire Hopkins; Marco Ferrari; Davide Mattavelli; Vittorio Rampinelli; Fabio Facchetti; Piero Nicolai; Paolo Bossi; Oswaldo A Henriquez; Kelly Magliocca; C Arturo Solares; Sarah K Wise; Jose L Llorente; Zara M Patel; Jayakar V Nayak; Peter H Hwang; Peter D Lacy; Robbie Woods; James P O'Neill; Amrita Jay; Dawn Carnell; Martin D Forster; Masaru Ishii; Nyall R London; Diana M Bell; Gary L Gallia; Paolo Castelnuovo; Stefano Severi; Valerie J Lund; Ehab Y Hanna
Journal:  Eur J Cancer       Date:  2021-12-31       Impact factor: 10.002

Review 3.  Exclusively endoscopic surgical resection of esthesioneuroblastoma: A systematic review.

Authors:  Daniel B Spielman; Andi Liebowitz; Maeher Grewal; Chetan Safi; Jonathan B Overdevest; Alfred M Iloreta; Brett E Youngerman; David A Gudis
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2022-03-22

Review 4.  Esthesioneuroblastoma: Summary of Single-center Experiences with Focus on Adjuvant Therapy and Overall Survival.

Authors:  Hammam A Alotaibi; Stefano M Priola; Anne-Laure Bernat; Faisal Farrash
Journal:  Cureus       Date:  2019-06-13

5.  Adrenocorticotropic Hormone-Secreting Esthesioneuroblastoma with Ectopic Cushing's Syndrome.

Authors:  Young Soo Chung; Minkyun Na; Cheol Ryong Ku; Se Hoon Kim; Eui Hyun Kim
Journal:  Yonsei Med J       Date:  2020-03       Impact factor: 2.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.